Holen Sie sich die Stockscreener-App
57.99
2.31%
-1.375
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Planned stock sale at Enliven Therapeutics (NASDAQ: ELVN) tops the million-dollar mark - Stock Titan
Enliven's Morgan Stanley conference chat will be webcast Sept. 16 - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (ELVN) Stock Price, News & Analysis - MarketBeat
Enliven will present leukemia drug data twice at a Houston meeting - Stock Titan
Discipline and Rules-Based Execution in ELVN Response - Stock Traders Daily
Enliven Therapeutics Presents ELVN-001 Data at SOHO Annual Meeting - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - kalkine.ca
Enliven (ELVN) Earnings Snapshot: EPS Falls Short of Its Estimate in the Reported Period; Share Response: The Stock Records a 0.79% Decrease on the DayProfit Cycle Analysis - vinanet.vn
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Stocktwits
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl Executes Two Stock Sales on August 17 Under 10b5-1 Plan - Kalkine Media
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan - Stock Titan
Enliven Therapeutics (ELVN) CMO exercises options, sells stock - Stock Titan
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - Moomoo
Enliven Therapeutics CMO Helen Louise Collins Executes Stock Option and Sells 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Enliven Therapeutics, Inc. /US/ Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
What's Going On With Enliven Therapeutics Stock Tuesday?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven a new outperform at Barclays on potential of CML asset - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho - MarketBeat
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com Canada
William Blair Initiates Enliven Therapeutics at Outperform - marketscreener.com
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN - MarketBeat
FMR LLC Boosts Stake in Enliven Therapeutics Inc (ELVN) with Str - GuruFocus
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (ELVN) Pulls Back 1.44% to $58.56 as Support HoldsFactor ETF Flow - dars.gov.et
Certain Options of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026. - marketscreener.com
Certain Common Stock of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026. - marketscreener.com
How (ELVN) Movements Inform Risk Allocation Models - Stock Traders Daily
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Enliven Therapeutics director Mika Derynck sells $9.56m shares By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Enliven Therapeutics (ELVN) and Geron (GERN) - The Globe and Mail
We're Interested To See How Enliven Therapeutics (NASDAQ:ELVN) Uses Its Cash Hoard To Grow - Moomoo
Enliven Therapeutics director Mika Derynck sells $9.56m shares - Investing.com
Enliven Therapeutics (ELVN) director exercises options, sells 158,795 shares - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 158,795 Shares of Stock - MarketBeat
Insider Sale: Director at $ELVN Sells 158,795 Shares - Moomoo
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82 - Moomoo
Enliven Therapeutics, Inc. Stock 12‑Month Price Target Raised to $70.9, Implies 19% Upside - TradingView
Enliven Therapeutics director Mika K. Derynck sells USD 9.56 million in common shares - Bitget
Stifel Nicolaus Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - marketbeat.com
FMR LLC and Abigail Johnson disclose 15% Enliven Therapeutics (ELVN) ownership - stocktitan.net
Guggenheim lowers Enliven Therapeutics stock price target to $78 By Investing.com - Investing.com Canada
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
ENLIVEN THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $69 FROM $59 - Bitget
Enliven Therapeutics, Inc. 2Q 2026: Net loss $32.5M, EPS $(0.49) — 10-Q Summary - TradingView
ELVN: Strong Phase 1 results and FDA alignment set up ENABLE-2 trial, with $895M cash runway into 2030 - TradingView
ELVN: Net loss widened on higher R&D costs; strong cash reserves support pivotal ELVN-001 trial - TradingView
Enliven Therapeutics (NASDAQ: ELVN) raises $460M, ends Q2 with $895M cash - Stock Titan
0.28%
4.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):